Lumen Technologies hires Sean Alexander as head of Connected Ecosystems
Investors are closely monitoring SCLX as it navigates through the headwinds that have led to this notable decline, seeking signs of potential recovery or further indicators of market pressures that could influence the stock’s performance in the upcoming quarters. With analyst price targets ranging from $4 to $22, InvestingPro subscribers can access 8 additional key insights about SCLX’s financial health and future prospects. With analyst price targets ranging from $4 to $22, InvestingPro subscribers can access 8 additional key insights about SCLX’s financial health and future prospects. Investors are closely monitoring SCLX as it navigates through the headwinds that have led to this notable decline, seeking signs of potential recovery or further indicators of market pressures that could influence the stock’s performance in the upcoming quarters.
In other recent news, Scilex Holding Company has made significant strides in its operations and financial performance. The company recently completed a $17 million direct stock and warrant offering, a strategic move aimed at bolstering general corporate purposes, including research and development, commercialization, and potential acquisitions or debt repayment. Scilex has also submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for ELYXYB, a treatment for acute pain, as part of its commitment to offering non-opioid alternatives in pain management.
Furthermore, Scilex has formed a joint venture with IPMC, named Scilex Bio, to develop and commercialize KDS2010, a new treatment for obesity and neurodegenerative diseases currently in Phase 2 clinical trials. This venture could potentially diversify Scilex’s therapeutic offerings beyond pain management.
In a recent study, Scilex’s ZTlido patch was linked to reduced opioid use in pain management. Boral (OTC:BOALY) Capital has set a $22 target on Scilex shares, rating them a ’Buy’. This rating is bolstered by Scilex’s diverse portfolio of non-opioid pain management products, with SEMDEXA, a clinical-stage dexamethasone gel, being highlighted as a potential blockbuster opportunity.
Lastly, the U.S. Bankruptcy Court for the Southern District of Texas has approved an extension of the lock-up period for Scilex Holding Company’s Dividend Stock to April 14, 2025, a significant event for shareholders and potential investors. These are the recent developments in Scilex Holding Company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.